I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com
Welcome to
InOncology.com

A knowledge hub developed to provide information and education in oncology for healthcare professionals.

Rate this

Our activities at AACR 2019

Booth #2908
Atlanta, GA, USA
29 March – 3 April 2019
13 publications

Our activities at ELCC 2019

Booth #13a
2 publications
1 symposium
10 - 13 April 2019
Geneva, Switzerland
GioTag Study Podcast

Listen to this podcast on our real-world study of first-line afatinib* followed by osimertinib

NSCLC in focus: information and educational resources

MDM2-p53 antagonist MOA

Learn more about our MDM2-p53 antagonist^ and other investigational compounds

GioTag study: Real-world data on sequential EGFR TKI treatment

View more information on this real-world study of sequential therapy with first-line afatinib followed by osimertinib in EGFRm+ NSCLC

Treatment sequencing in EGFRM+ NSCLC

Learn more about sequencing of EGFR TKIs in this latest video with Nicolas Girard

Download Library resources

Browse freely available educational materials in our Download Library, including slide decks

inOncology Article Library

Search this library for published papers about afatinib and nintedanib**

Importance and impact of medical education meetings

Watch the Conversations in Oncology faculty share their thoughts on the benefits of medical education meetings for professionals treating cancer

Physicians’ insights
image
Dr Maximilian Hochmair

Sequencing in EGFR-mutated NSCLC: does order matter?

FIND OUT MORE
Edward S. Kim
Dr Edward Kim

Efficacy of EGFR TKIs in patients with uncommon mutations

FIND OUT MORE
image
Dr David Gandara

Maximising the clinical potential of TKIs for patients with squamous NSCLC

FIND OUT MORE
image
Dr Noemi Reguart

The challenge of preventing and managing brain metastases in EGFRm+ NSCLC

FIND OUT MORE
Sanjay Popat
Dr Sanjay Popat

Treating second-line and beyond in non-mutated, non-squamous NSCLC: now and tomorrow

FIND OUT MORE
Barbara Melosky
Dr Barbara Melosky

Clinical considerations in EGFRm+ NSCLC: does treatment sequence matter?

FIND OUT MORE
Professor Martin Schuler
Prof Martin Schuler

Improving outcomes for patients with brain metastases

FIND OUT MORE
<
>

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

^This is an investigational compound and has not been approved. Its safety and efficacy have not been established.